Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study.

European journal of human genetics : EJHG - 1 Jun 2016

Høberg-Vetti Hildegunn, Bjorvatn Cathrine, Fiane Bent E, Aas Turid, Woie Kathrine, Espelid Helge, Rusken Tone, Eikesdal Hans Petter, Listøl Wenche, Haavind Marianne T, Knappskog Per M, Haukanes Bjørn Ivar, Steen Vidar M, Hoogerbrugge Nicoline

Abstract excerpt

Germline BRCA1/2 testing of breast and ovarian cancer patients is growing rapidly as the result affects both treatment and cancer prevention in patients and relatives. Through the DNA-BONus study we offered BRCA1/2 testing and familial risk assessment to all new patients with breast (N=893) or ovarian (N=122) cancer diagnosed between September 2012 and April 2015, irrespective of family history or age, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anxiety
Share to BRCA1 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA2 Protein

Share to Breast Neoplasms

Share to Genetic Counseling

Share to Health Knowledge, Attitudes, Practice

Share to Ovarian Neoplasms

Share to Prevalence

Source

Open in PubMed Open full text

Identifiers

PMID: 26350514
DOI: 10.1038/ejhg.2015.196
PMCID: PMC4867439

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study.PMID 26350514Read ↗

Real-world multi-country study of BRCA1/2 mutation testing among adult women with HER2-negative advanced breast cancer.Semantic proximity Read ↗

Fertility Counseling in BRCA1/2-Mutated Women with Breast Cancer and Healthy IndividualsSemantic proximity Read ↗

Genetic testing in women with breast cancer: implications for treatment.Semantic proximity Read ↗

Utility of Expedited Hereditary Cancer Testing in the Surgical Management of Patients with a New Breast Cancer Diagnosis.Semantic proximity Read ↗

Germline BRCA testing is moving from cancer risk assessment to a predictive biomarker for targeting cancer therapeutics.Semantic proximity Read ↗

Association of Genetic Testing Results With Mortality Among Women With Breast Cancer or Ovarian Cancer.Semantic proximity Read ↗

The Knowledge and Attitude of Patients Diagnosed with Epithelial Ovarian Cancer towards Genetic Testing.Semantic proximity Read ↗

BRCA1 and BRCA2 Mutation Testing in Young Women With Breast Cancer.Semantic proximity Read ↗

Re-evaluating hereditary breast and ovarian cancer risk: clinical impact of updated multigene panel sequencing and genetic counseling.Semantic proximity Read ↗

BRCAsearch: written pre-test information and BRCA1/2 germline mutation testing in unselected patients with newly diagnosed breast cancer.Semantic proximity Read ↗

Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing.Semantic proximity Read ↗

BRCA1/2 Mutation Testing Among Adult Women With HER2-Negative Advanced Breast Cancer: Results From a Multi-Country, Real-World StudySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.